European Biotech Stocks 2010/IV
The EuroBiotech Stocks list offers a comparative tool for the performance of all listed European Biotech Stocks. To ease compatibility all quotes are converted to Euros. The performance is calculated over a period of 60 days before the effective date. Displayed highs and lows are taken from the last 52 weeks.
| 1 | Wilex (D) | 47.7% | 6.16 | 7.6/3.2 |
| 2 | Cytos (CH) | 47.4% | 11.32 | 16.2/6.7 |
| 3 | Ipsogen (F) | 34.7% | 7.75 | 9.6/5.5 |
| 4 | FuturaGene (UK) | 29.9% | 0.97 | 0.98/0.5 |
| 5 | Vectura (UK) | 26.8% | 0.5 | 1.12/0.37 |
| 6 | GeneArt (D) | 20.9% | 16.6 | 16.9/5 |
| 7 | Biocompatibles (UK) | 16.3% | 2.92 | 3/1.8 |
| 8 | Renovo (UK) | 14.8% | 0.29 | 0.37/0.25 |
| 9 | Magforce (D) | 13.5% | 46 | 48.9/36.5 |
| 10 | Advanced Med. Sol. (UK) | 9.1% | 0.5 | 0.52/0.26 |
| 11 | Bavarian Nordic (DK) | 6.1% | 39.39 | 40/21.5 |
| 12 | Virbac (F) | 5.6% | 89.29 | 95/56 |
| 13 | Oxford Biomedica (UK) | 5.4% | 0.1 | 0.24/0.1 |
| 14 | Vita 34 (D) | 4.1% | 5 | 6.3/4.2 |
| 15 | MediGene (D) | 4.1% | 2.77 | 5.5/2.4 |
| 16 | Fornix Bioscience (NL) | 3.5% | 4.62 | 10.3/4.4 |
| 17 | Evotec (D) | 3% | 2.02 | 2.5/1 |
| 18 | Abcam (UK) | 2.7% | 13.57 | N/A |
| 19 | Genmab (DK) | 2% | 8.05 | 29.1/5.4 |
| 20 | Orexo (S) | 1.7% | 4.07 | 4.7/3.3 |
| 21 | Ablynx (B) | 1.6% | 7.29 | 8.5/5.5 |
| 22 | Biotest VZ (D) | 1.3% | 34.5 | 45.2/29.5 |
| 23 | Mologen (D) | 1.2% | 9.26 | 10/6.3 |
| 24 | MorphoSys (D) | .7% | 15.31 | 19/13.4 |
| 25 | Active Biotech (S) | .7% | 10.51 | 13.2/3.8 |
| 26 | Alizyme (UK) | 0% | 0.01 | 0.17/0.02 |
| 27 | Biotie (FIN) | 0% | 0.36 | 0.55/0.4 |
| 28 | MolMed (I) | 0% | 1.89 | 1.93/0.68 |
| 29 | 4SC (D) | 0% | 2.79 | 3.6/2.4 |
| 30 | Elan (IRL) | 0% | 5.41 | N/A |
| 31 | Genfit (F) | 0% | 7.08 | 8.3/5.2 |
| 32 | Cellectis (F) | 0% | 8.8 | 14.4/7.6 |
| 33 | Novozymes (DK) | -0.6% | 87.48 | 95/55.4 |
| 34 | DSM (NL) | -1.2% | 32.9 | 35.4/21.3 |
| 35 | Galapagos (B) | -1.8% | 10.63 | 12.2/7.1 |
| 36 | Paion (D) | -2.5% | 1.88 | 3.35/0.89 |
| 37 | BioXell (I) | -3.1% | 4.23 | 5.2/29.9 |
| 38 | Sygnis Pharma (D) | -4% | 0.94 | 1.33/0.77 |
| 39 | Fulcrum Pharma (UK) | -4.7% | 0.05 | 0.07/0.02 |
| 40 | Biofrontera (D) | -4.9% | 2.12 | 3.4/1.2 |
| 41 | AB Science (F) | -4.9% | 11.88 | 13/9.9 |
| 42 | Crucell (NL) | -5.1% | 14.68 | 17.6/12.5 |
| 43 | GW Pharmaceut. (UK) | -6.6% | 1.2 | 1.72/0.76 |
| 44 | Devgen (B) | -7% | 8.36 | 12.6/6.1 |
| 45 | Analytik Jena (D) | -7.2% | 9 | 11.4/8 |
| 46 | Sareum (UK) | -7.4% | 00 | 0.01/0 |
| 47 | UCB (B) | -7.8% | 25.73 | 33.8/21.5 |
| 48 | Sartorius VZ (D) | -8.2% | 19.55 | 22.4/8 |
| 49 | Roche GS (CH) | -8.2% | 104.17 | 128.5/99.8 |
| 50 | Actelion (CH) | -8.6% | 26.82 | 43.8/26 |
| 51 | Agennix AG (D) | -8.7% | 4.28 | 7.2/1.1 |
| 52 | Qiagen (D) | -9.4% | 15.68 | 17.9/12.4 |
| 53 | Thrombogenics (B) | -9.9% | 15.11 | 18.8/10.7 |
| 54 | Zeltia (E) | -10.1% | 3.27 | 5.7/2.6 |
| 55 | Cosmo (I) | -10.3% | 11.75 | 16.1/9.9 |
| 56 | BB Biotech (CH) | -11.1% | 41.49 | 52.2/41.2 |
| 57 | Syngenta (CH) | -12.1% | 155.43 | 202.3/146.4 |
| 58 | Biolin (S) | -12.9% | 0.95 | 1.32/0.65 |
| 59 | Eurofins Scientific (F) | -13% | 28.87 | 43.5/26.7 |
| 60 | BioAlliance (F) | -15.1% | 5.21 | 6.7/3.6 |
| 61 | Transgene (F) | -15.4% | 13.56 | 23.2/12.5 |
| 62 | ProStrakan (UK) | -16.3% | 0.74 | 1.71/0.7 |
| 63 | Phytopharm (UK) | -16.8% | 0.08 | 0.4/0.05 |
| 64 | Almirall (E) | -16.8% | 6.65 | 10.2/6 |
| 65 | Lonza (CH) | -17.1% | 45.06 | 76.2/43.5 |
| 66 | Octoplus (NL) | -17.4% | 1.09 | 1.9/1 |
| 67 | Addex Pharma (CH) | -17.6% | 6.49 | 27.8/6.2 |
| 68 | Epigenomics (D) | -18.3% | 2 | 4/1.9 |
| 69 | Photocure (N) | -18.9% | 4.64 | 6.5/3.8 |
| 70 | Henderson Morley (UK) | -19% | 00 | 0.01/0 |
| 71 | Antisoma (UK) | -20% | 0.06 | 0.43/0.05 |
| 72 | HBM Bioventures (CH) | -20.3% | 25.69 | 34/18.5 |
| 73 | Deinove (F) | -21.7% | 6.16 | 8.4/4.9 |
| 74 | Chronotech (S) | -21.8% | 0.06 | 0.22/0.06 |
| 75 | Neovacs (F) | -21.9% | 3.2 | 4.8/2.8 |
| 76 | Algeta (N) | -22.4% | 8.46 | 12.5/4.2 |
| 77 | Plethora (UK) | -22.4% | 0.12 | 0.35/0.1 |
| 78 | Basilea (CH) | -22.8% | 38.21 | 76.2/36.1 |
| 79 | Vivalis (F) | -23.8% | 7 | 11.2/7 |
| 80 | Diagenic (N) | -24.3% | 0.28 | 0.52/0.25 |
| 81 | Clavis Pharma (N) | -24.7% | 4.75 | 7.3/1.7 |
| 82 | Metabolic Explorer (F) | -24.8% | 4.96 | 8/4.8 |
| 83 | Oncomethylome (B) | -24.8% | 1.71 | 7.4/1.6 |
| 84 | Evolva (CH) | -25.1% | 1.35 | 4.97/0.44 |
| 85 | Intercell (A) | -26.7% | 14.25 | 29.3/13.5 |
| 86 | Pronova (N) | -27.1% | 1.63 | 2.6/1.5 |
| 87 | Proximagen (UK) | -27.5% | 0.85 | 1.46/0.77 |
| 88 | Biotec Pharmacon (N) | -29.5% | 0.59 | 5.07/0.39 |
| 89 | TopoTarget (DK) | -29.9% | 0.44 | 0.79/0.31 |
| 90 | Ipsen (F) | -31.2% | 24.78 | 42.2/24.1 |
| 91 | ExonHit (F) | -31.9% | 2.47 | 7/2.4 |
| 92 | Vernalis (UK) | -34.6% | 0.35 | 1.23/0.34 |
| 93 | Tigenix (F) | -35% | 1.64 | 5/1.6 |
| 94 | Pharming (NL) | -36.3% | 0.2 | 0.64/0.16 |
| 95 | Affitech (DK) | -39.9% | 0.05 | 0.19/0.04 |
| 96 | Axis-Shield (UK) | -43.4% | 2.71 | 5/2.6 |
| 97 | Silence Therapeutics (UK) | -47.4% | 0.05 | 0.29/0.05 |
| 98 | Decode (IC) | -50% | 0.01 | 0.6/0 |
| 99 | ReGen Therapeutics (UK) | -56.2% | 0.01 | 0.07/0.01 |
| 100 | Ark Therapeutics (UK) | -59.9% | 0.04 | 0.59/0.05 |
| 101 | Nicox (F) | -65.3% | 2.77 | 10.2/2.3 |
| 102 | Santhera (CH) | -67.1% | 5.54 | 21.1/5 |
| 103 | Newron (I) | -67.3% | 4.32 | 17.7/4 |
Performance for 60 days, Highs and lows in 52 weeks.